paclitaxel + S-1 + tislelizumab

paclitaxel + S-1 + tislelizumab is an investigational chemo-immunotherapy combination regimen being evaluated for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers, particularly those with peritoneal metastasis. The regimen integrates **tislelizumab**, a humanized IgG4 monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses, with two cytotoxic agents: **paclitaxel**, a taxane that stabilizes microtubules to inhibit cell division, and **S-1**, an oral fluoropyrimidine formulation. S-1 contains tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (which reduces gastrointestinal toxicity). In the clinical trial setting led by Hebei Medical University, this combination is utilized within a conversion therapy framework involving hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) to improve resectability and outcomes in patients with peritoneal involvement.

Other names

HIPEC + NIPS + tislelizumab